Q&A with Melanoma March Fundraisers
10 March 2015
Adrienne and Georgia lost their mother Patricia in 2009. They are taking part in this year's Melanoma March for the second time and hope that with their fundraising they can help another family go through what they had to. Read about how they are rallying their team together and hope to raise as much as possible.
Why are you taking part in this years Melanoma March?
We are taking part in this year's Melanoma March as we sadly lost our mother in 2009 to this aggressive disease. Mum first found her mole on the inside of year leg 14 years prior to her death. Adrienne was in year 1 and Georgia was in year 11. At the time, both of us didn’t quite comprehend the seriousness of her illness, nor did we expect that it would return some years later. Mum went into remission and in 2008 we discovered that the cancer had returned and was growing in her abdomen. After major surgery to remove the cancer we received the news that the cancer had spread to many of Mum’s organs. Within a few months it eventually reached her brain and Mum lost her battle. Our Mum wasn’t lucky enough to have the option of the trials and programs that are offered to melanoma patients now. Upon her first diagnosis in 1994 there were very limited options and when the cancer returned, it was too late for her. We are marching to raise awareness of melanoma in the hope that people avoid the harsh sun, understand the dangers of UV exposure and maintain regular skin check ups – whether they have had melanoma in the past, are predisposed to it or just need to keep an eye out for changes. In addition to raised awareness it is so important to continue to raise funds in order to fund important trials. We can only dream about what could have been a better outcome for our mother. Yet we hope that other individuals can get access to such valuable treatment that our mum couldn’t. If our fundraising can help the lives of another family to not go through what we did, we will do all we can.
How are you fundraising for your team?
We have contacted all our friends and families and asked them to march with us or make a donation to our team. Friends are holding morning teas at work to rally marchers and raise funds. Adrienne is a school teacher and will be sharing her story and having a guest speaker at her school this week.
How many people are in your team?
At present we have around 20 marchers who will be walking with us. We hope this number will continue to grow this week!
What are some of your tips to get your friends and family to donate?
The power of social media is great. We have been posting daily reminders to donate and register and set up a facebook event which we regularly update. Sending out SMS reminders has also been effective. We find that thanking people publicly on Facebook everytime we receive a donation helps to remind people as well as provide positive encouragement for others! We have asked members of our team to repost the link to register and donate. The last year our team marched in Manly we raised over $2000. We are close to $1000 at the moment and are pushing for more donations to come through this week. It would be amazing to match or beat our last effort. We find that most people donate in the week leading up to the event.
Donate now. Every bit counts towards a cure.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.